Novartis Ag (NVSEF) Operating Leases (2019 - 2025)

Novartis Ag has disclosed Operating Leases across 7 years of filings, most recently posting $1.7 billion for Q4 2025.

• Operating Leases for Q4 2025 came in at $1.7 billion, up 3625.53% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.7 billion (up 3625.53% YoY), and the FY2025 annual result was $1.7 billion, up 3625.53% from the prior year.
• Operating Leases came in at $1.7 billion for Q4 2025 at Novartis Ag, up from -$47.0 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $1.9 billion in Q4 2021 to a low of -$47.0 million in Q4 2024.
• The 5-year median for Operating Leases is -$12.0 million (2022), against an average of $399.3 million.
• Across the five-year window, Operating Leases soared 4409.09% in 2021 and slumped 132.19% in 2024, its largest moves.
• Novartis Ag's Operating Leases stood at $1.9 billion in 2021, then sank by 98.79% to $23.0 million in 2022, then jumped by 534.78% to $146.0 million in 2023, then plunged by 132.19% to -$47.0 million in 2024, then jumped by 3625.53% to $1.7 billion in 2025.
• The last three Operating Leases figures came in at $1.7 billion (Q4 2025), -$47.0 million (Q4 2024), and -$45.0 million (Q3 2024), per Business Quant data.